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Background: Although even randomization (that is, approximately 1:1 randomization ratio in study arms) provides
the greatest statistical power, designed uneven randomization (DUR), (for example, 1:2 or 1:3) is used to increase
participation rates. Until now, no convincing data exists addressing the impact of DUR on participation rates in
trials. The objective of this study is to evaluate the epidemiology and to explore factors associated with DUR.
Methods: We will search for reports of RCTs published within two years in 25 general medical journals with the
highest impact factor according to the Journal Citation Report (JCR)-2010. Teams of two reviewers will determine
eligibility and extract relevant information from eligible RCTs in duplicate and using standardized forms. We will
report the prevalence of DUR trials, the reported reasons for using DUR, and perform a linear regression analysis to
estimate the association between the randomization ratio and the associated factors, including participation rate,
type of informed consent, clinical area, and so on.
Discussion: A clearer understanding of RCTs with DUR and its association with factors in trials, for example,
participation rate, can optimize trial design and may have important implications for both researchers and users of
the medical literature.
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Well-designed and implemented randomized controlled
trials (RCTs) are considered the ‘gold-standard’ for
evaluating the effects of health care interventions. How-
ever, the recruitment of participants to RCTs can be
extremely difficult [1,2]. For example, in a review of 41
RCTs [3], a large proportion (66%) failed to achieve their
planned sample size [4-6]. In the same review [3], those
who refused to participate accounted for 27% of those
eligible, thus limiting the generalizability of the findings.
Patient preferences for a particular treatment option
are reported as the top barrier to participation in RCTs
[7]; the key reasons for the refusal to participate are
usually the rejection of receiving placebo or other in-
active therapy [8,9]. Several investigators report [10] that* Correspondence: schuneh@mcmaster.ca
3Department of Clinical Epidemiology & Biostatistics, McMaster University,
Hamilton, ON, Canada
Full list of author information is available at the end of the article
© 2014 Wu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.patients who thought that the experimental treatment
was better than standard treatment were more likely to
consent to participation in RCTs [11,12]. Thus, a greater
chance of receiving active treatment rather than placebo
or control therapy may lead to greater participation
in RCTs.
Encouraging patient enrollment is one of the main rea-
sons for designed uneven randomization (DUR), such as
1:2 or 1:3 or greater [2,13,14]. Other reasons include redu-
cing costs, avoiding presumed risks (for example, toxicity),
or increasing the amount of information on safety/adverse
events of an intervention [15-17]. A DUR trial can be
defined as a trial that is pre-planned to include a different
numbers of participants in the experimental and control
groups. However, so far, investigators have not comprehen-
sively examined the reasons for conducting DUR trials and
the impact of DUR on participation rate.
Treweek et al. [18] systematically reviewed randomized
and quasi-randomized controlled trials evaluating the effect. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Wu et al. Trials 2014, 15:33 Page 2 of 7
http://www.trialsjournal.com/content/15/1/33of strategies to improve recruitment of participants to
RCTs. Their results showed that participation rates might
be influenced by a number of factors [18] such as study de-
sign, consent form, approach made to potential participants
or financial incentives for participants, but there was not
enough data to rule out or confirm a significant effect of
DUR. Two studies [10,19] included in the systematic review
evaluated various combinations of pre-randomization and
consent. One study recruited 3,217 healthy participants
who were predominantly young males with a high level of
education. Another was a mock anesthesia trial, in which
participants were asked to choose between different
anesthetic drugs. The applicability of these results remains
uncertain given the hypothetical nature of the exercise [10].
Thus, until now, no convincing data that addresses the
impact of DUR on factors, such as participation rates, in
trials exists despite the more than anecdotal use and
publications of DUR trials in high impact journals
[20-25]. The primary objective of this study is to explore
factors associated with DUR. The secondary objectives
are to describe (1) the epidemiology, (2) the justification
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Figure 1 Flow chart of the methodological survey of designed unevehighest impact factor according to the Journal Citation
Report (JCR)-2010 (Figure 1). Eligible trials are designed
DUR trials without a limitation on the exact ratio. This
study satisfied the ethical requirements of the Hamilton
Health Sciences/Faculty of Health Sciences Research
Ethics Board.
Definitions
We define a DUR RCT to have pre-planned uneven num-
bers of participants in the experimental and control groups,
including studies with more than two arms. We will contact
the study authors to definitively establish if the study was
pre-planned to have an uneven number of participants in
experimental and control groups if published material, such
as protocols or reports of the results, do not provide suffi-
cient information.
If trial authors do not respond to our queries, two investi-
gators will make independent judgments and reach consen-
sus, if necessary with help from a third investigator. The
criteria for the judgment will include: (1) for studies with
total sample sizes of less than 1,000, if the randomization
ratio was equal to or larger than 1.25; or (2) for studies with
total sample size equal to or greater than 1,000, if the
randomization ratio was equal to or larger than 1.05, we
will consider them as DUR. Small changes in group size in
small sample trials may have a higher impact on the ratio
than in larger sample size trials. Thus, we decided to use




factors, e.g. reasons for
non-participation, in the
DURs
Search for published materials 
or contact the authors to
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highly sensitive identification of DUR trials. The rationale,
based on a preliminary literature review, was as follows.
First, 7:6(1.17) [26] was the smallest ratio mentioned by au-
thors of DUR trials, and 1.05 was a relatively low threshold.
We assume that any trial with a ratio equal or below 1.05
has a less than 5% possibility of being a DUR trial. In our
scoping exercise, we have not detected any trial with a ratio
lower than 1.05 as a DUR trial or larger than 1.25 as a non-
DUR trial. To calculate the randomization ratio, we used
the larger group divided by the smaller one. For instance, if
the sample size of the experimental group is 550, and the
control group is 520, then 550/520 = 1.06; or if the experi-
mental group’s sample size is 520, and the control group is
550, the ratio should still be 550/520 = 1.06.
We defined participation rate as the proportion of
eligible individuals who participated; that is, number of
eligible individuals (NEI) minus number of individuals
declining to participate (NIDP) divided by number of
eligible individuals (NEI):
Participation rate = (NEI-NIDP)/NEI
We will also calculate a recruitment rate as the pro-
portion of participating individuals out of those actually
approached in the trials as follows:
Recruitment rate = Participated individuals/Approached
individuals.Eligibility criteria
1. RCT designed with an uneven randomization;
2. RCT assessing at least one patient important
outcome, defined as one for which one would
answer the following question with ‘yes’: ‘If the
patient knew that this outcome was the only thing
to change with treatment, would the patient
consider receiving this treatment if it was associated
with adverse effects, inconvenience, or cost?’ Such
outcomes include mortality, morbidity, and
outcomes reported by patients. We will consider
surrogate outcomes (such as changes in blood
pressure, HbA1c) as not important to patients [27];
3. Superiority trials (that is trials that are designed to
demonstrate that one treatment is more effective
than another).
We will exclude trails if they are (1) an N-of-1 RCT;
(2) a RCT reported in a research letter; (3) reports of
secondary analysis of previously published RCTs; (4) re-
ports of subgroup analysis of previously published RCTs;
(5) previously reported RCTs (for example, longer
follow-up or a second trial included approximately the
same amount of participants as the first one); (6) cross-
over RCT; (7) factorial design; (8) cluster RCT.When we are analyzing the impact of DURs on par-
ticular factor, such as participation rate, we will exclude
(1) trials with more participants in the control group
than in the experimental group, which is a ratio of par-
ticipants in control versus experimental group larger
than 1.25; or (2) trials omitting to describe obtaining in-
formed consent from participants.
Literature search
Eligible studies will be searched among the highest
ranked 25 general medical journals according to the
number of citations reported in the JCR by Thomson
ISI (Institute for Scientific Information) in 2010: New
England Journal of Medicine (NEJM), Lancet, Journal of
the American Medical Association (JAMA), Annals of In-
ternal Medicine (AIM), PLOS Medicine, British Medical
Journal (BMJ), Archives of Internal Medicine, Canadian
Medical Association Journal (CMAJ), Journal of Internal
Medicine, BMC Medicine, MAYO Clinic Proceedings
(MCP), American Journal of Medicine (AJM), Annals of
Family Medicine, Annals of Medicine, Medicine, American
Journal of Preventive Medicine (AJPM), Cleveland Clinic
Journal of Medicine (CCJM), Preventive Medicine (PM),
British Medical Bulletin (BMB), American Journal of
Managed Care (AJMC), Translational Research, Medical
Clinics of North America (MCNA), Journal of General
Internal Medicine (JGIM), European Journal of Clinical
Investigation (EJCI), Medical Journal of Australia (MJA).
Two journals, Annual Review of Medicine and Cochrane
Database Systematic Review, which focus on review
articles, were not included. We will search Medline
(OVID interface) using the Cochrane Collaboration’s ‘highly
sensitive’ search strategy to identify RCTs (Additional file 1).
Review process
Working in pairs, reviewers will select studies (title/
abstract screening and full-text screening) and abstract
data, in duplicate and independently. Disagreements
will be discussed and resolved between each pair of
reviewers, if necessary with help of an arbitrator. Two
investigators (DW, HJS) will serve as the arbitrators
for all studies. We will use electronic forms for title
and abstract screening, for full-text screening, and for
data abstraction.
Selection of studies
Reviewers will first screen the titles and abstracts of the
identified citations for potentially eligible RCT reports.
Then, they will screen full-texts of potentially eligible
RCT reports using an electronic, standardized spread-
sheet with corresponding written instructions. We will
prepare detailed written instructions. Before extracting
data from DUR trials, we will contact the study authors
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cation was a product of chance.
Sample size
Applying our search strategy to the years 2010 to 2011, we
estimate that we will identify approximately 150 eligible
DUR papers. For three plausible levels of participation rate,
25%, 50% and 75%, in non-DUR trials, with three respective
minimal important increases of 5.3%, 10%, and 11.7% in
DUR trials, a sample size of 150 would result in 95% confi-
dence intervals (95% CIs) for those increases of (23% to
38%); (52% to 68%) and (81% to 92%), respectively. We de-
termined the minimal important increase for three different
levels of participation rate based on the responses of a brief
survey amongst colleagues (Additional file 2).
In the regression analysis, the dependent variable will
be the participation rate, and we estimate that ten inde-
pendent variables, including the randomization ratio,
will be included in the final model. It is widely accepted
that one can use one independent variable per ten oc-
currences of the dependent variables in a linear regres-
sion analysis, which means that 150 eligible DUR trials
will be sufficient for the regression analysis.
Data abstraction
We will conduct a comprehensive search for all pub-
lished material of each included DUR trial in order to
gather all the available information about the participa-
tion rate. This material includes, for example, protocols,
appendices, supplementary documents or other relevant
published articles. However, for some of the RCTs we
may not be able to gather sufficient information.
For all the reports of eligible DUR trials, we will ex-
tract information about the study design, methodological
quality, and DUR-related data using a pilot-tested stan-
dardized data abstraction form (Additional file 3):
1. Design information
We extracted data on: number of study centers,
ratio of randomization, clinical area, type of
intervention, type of control, number of arms, total
number of randomized participants, planned sample
size and primary and secondary outcomes. We will
also record measures to encourage recruitment (for
example, telephone reminder).
2. Methodological quality
We will determine the methodological quality by
abstracting the following factors: blinding, allocation
concealment, premature discontinuation and reason
for stopping. We will use ‘definitely yes/probably
yes/probably not/definitely not’ as judgment options
in the data abstracting of blinding [28], and will
determine the category of concealment of allocation
(see Additional file 3 for more details).3. DUR data
We will collect reasons for DUR, reported baseline
characteristics of those non-participants (yes/no), as
well as number of non-participants due to different
reasons when reported by the trial. We divided the
reasons for those choosing to Not Participate into
three types, that is, (1) Subjective reason: not to par-
ticipate was due to subjective reasons, such as not
interested; (2) Unclear reason: reasons that were
reported as ‘unclear’ or not reported; and (3) Other
reason: all the reasons in between, we consider as
Other reasons. Possible descriptions of the reasons
and the corresponding categories are listed in
Additional file 4.
Information as number of authors contacted, type of
consent (opt-out or opt-in), duration of recruitment,
type of randomization ratio, report of CONSORT
flow diagram and financial incentives for participants
will be abstracted.
4. Others
We will identify data that is inconsistent in the
report (for example, differences between the results
section and tables), as well as factors reported by the
authors that might impact on the participation rate.
If the reasons for persons refusing to participate or if
the number of eligible persons were not clearly or
completely reported, we will provide study authors
with the opportunity to confirm or refute the
abstracted data by contacting and sending them the
key results of our data abstraction, such as number
of persons refusing to participate due to different
reasons.Data analysis
Descriptive of the data
We will report the design information of DURs, number
of study centers, clinical areas that were covered, type of
intervention, type of control, number of arms, planned
sample size, the outcomes and measures to encourage
recruitment.
Methodological quality of DURs will be reported for
several factors: type of blinding, allocation concealment,
trials stopped early and the reasons for stopping.Reporting of DUR information
We will calculate the proportion of RCTs that are DUR
trials using the total number of RCTs as the denomin-
ator for each publication year (2010 and 2011). We will
also calculate the proportions of DUR trials (1) reporting
a CONSORT flow diagram; (2) reporting details about
the informed consent procedure; (3) reporting UNCLEAR
as reason of non-participation; (4) reporting reasons for
using DUR.
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uncertainty about whether or not they were DUR trials,
that is, we cannot obtain any information from the pub-
lished materials or any response from the authors and
the randomization ratio is between 1.05 and 1.25, we are
planning a sensitivity analysis of this group of trials des-
pite their sample sizes. All the above calculations of
DUR trails will also be reported based on this sensitivity
analysis.
Reporting of participation rate
We will report the participation rate for DUR trials. If
the number of eligible individuals was not reported, and
no further information could be obtained from the au-
thors, meaning that we will be unable to determine the
participation rate, we will use a median participation rate
of the other studies in the same clinical area and per-
form a sensitivity analysis.
Methods used for analyzing reported participation rate
The unit of analysis will be the individual trial. We will
conduct a linear regression analysis to estimate the asso-
ciation between the randomization ratio and the per-
centage of non-participation due to subjective reasons.
The dependent variable in this analysis will be the par-
ticipation rate. Our main predictor of interest is the
randomization rate. We will also include type of in-
formed consent, clinical area, type of design, number of
arms, measures to encourage recruitment, duration of
recruitment, and financial incentives for participants as
independent variables.
In addition, we will perform an analysis considering
the influence of the randomization ratio on the overall
non-participation rate.
Subgroup analysis
We will perform subgroup analysis on (1) patient-
reported or no patient-reported outcomes; (2) single or
multiple experimental arms, to determine which factors
were more likely to impact the participation rate.
Discussion
This protocol describes a methodological study aiming
to evaluate the epidemiology and to explore factors asso-
ciated with DUR. Strengths of our study protocol include
a systematic literature search with the goal of compiling a
comprehensive sample of DUR trials, and the transparent
and systematic methods used with respect to selecting
eligible studies and abstracting data.
We will focus on reports of trials published in the top
25 general medical journals that are more likely to influ-
ence clinical practice than those published in lower pro-
file journals. Moreover, RCTs published in these major
medical journals are typically of higher methodologicalquality [29], and tend to report more detailed informa-
tion on reasons for non-participation than studies with
lower impact profile. However, the representativeness of
our study may be limited because of the decision to
focus on high impact journals.
There are several potential reasons for using DUR. In
RCTs with a fixed budget, DURs may increase the power
of the trial by allowing more participants to be recruited
in the least expensive trial arm [30]. Also, DUR may
have ethical advantages by reducing the number of sub-
jects exposed to a potentially dangerous treatment [16],
as well as by increasing the number of subjects who
would be randomized to what was thought to be the
superior therapy [15]. Encouraging patient enrollment
and increasing compliance in a placebo-controlled trial
are other reasons for DUR [31]. Moreover, unequal allo-
cation is commonly used to increase the probability of
success in multi-stage adaptive design studies [32].
Although the power of the t-test for the difference in
means of two groups is maximized with equal sample
sizes [33], Lachin [34] pointed out that the gain in power
is trivial. For large trials (total n > 200), the susceptibility
of a randomization procedure to such imbalances appears
not be of statistical concern. Additionally, McEntegart and
Dawson [35] commented that maximizing power for pair-
wise comparisons is a reason for unequal allocation in
dose-response studies.
The accuracy of our results will depend on the number
of DUR trials we will identify and the number of other fac-
tors we will abstract; for example, individuals who decline
to participate even when they are eligible. Though the
CONSORT statement [36] recommends that authors give
detailed information about those who were excluded due to
a variety of reasons, the available information indicated that
inadequate reporting of non-participation is a greater prob-
lem than anticipated [37]. In this study, without a concur-
rent control group of pre-planned even randomization
ratio (1:1) trials, we cannot quantitatively estimate the effect
of DUR on a specific factor. On the basis of the result of
our study, we may be able to do further research to com-
pare the relative risk (RR) of a specific factor which is
closely associated with DRU with the RR from matching
non-DUR trials.
It is very likely that investigators, journal editors, and
clinical experts remain unaware of the problems associated
with inadequate participant recruitment, ranging from
inconclusive numbers to possible alteration of the study
results [37]. Hunninghake and his colleagues [37] noted
that accrual rates are often not clearly reported. Also, they
were unable to estimate how many studies were terminated
or yielded inconclusive results because of inadequate
participant recruitment.
Findings of our study may influence recommendations
on how detailed information should be included when the
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search strategies (with the goal of compiling a comprehen-
sive sample of RCTs with uneven randomization, and inde-
pendent evaluation of all the eligible RCTs) and statistical
analysis with sufficient power, we could provide useful
information of the epidemiology and factors, for example,
participation rate, associated with DUR. Evidence of vulner-
ability of participation recruitment will call for improving
study design and trial implementation to increase participa-
tion rate. Our study should make a significant contribution
to the methodology of RCTs and provide guidance for
trialists and those interpreting RCTs.
Additional files
Additional file 1: Search strategy for Medline using OVID interface.
Additional file 2: Disclosure form of the survey on Minimal
Important Difference.
Additional file 3: Data Abstraction Form.
Additional file 4: Examples of each type of non-participation
reasons.
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